CN3 PHARMACOECONOMIC (PE) ANALYSIS OF THE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) IN THE NETHERLANDS DEMONSTRATES THAT ERLOTINIB DOMINATES DOCETAXEL AND IS COST-EFFECTIVE OVER BEST SUPPORTIVE CARE (BSC) WITHOUT NEED FOR PATIENT STRA ...
Nov 1, 2006, 00:00
10.1016/S1098-3015(10)63205-6
https://www.valueinhealthjournal.com/article/S1098-3015(10)63205-6/fulltext
Title :
CN3 PHARMACOECONOMIC (PE) ANALYSIS OF THE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) IN THE NETHERLANDS DEMONSTRATES THAT ERLOTINIB DOMINATES DOCETAXEL AND IS COST-EFFECTIVE OVER BEST SUPPORTIVE CARE (BSC) WITHOUT NEED FOR PATIENT STRA ...
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)63205-6&doi=10.1016/S1098-3015(10)63205-6
First page :
Section Title :
Open access? :
No
Section Order :
56